$NURO News
Last published 1y ago
- 1y agoECORNUROelectroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic TechnologiesGlobeNewswireROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the
- 1y agoBKTIBRNKFSLMB+1Kingsway Financial Services Inc. Appoints Adam J. Patinkin and Joshua S. Horowitz to Its Board of DirectorsACCESS NewswireCHICAGO, ILLINOIS / ACCESS Newswire / March 31, 2025 / Kingsway Financial Services Inc. today announced it has appointed Adam J. Patinkin and Joshua S.
- 1y agoPWODNUROBHLBBRKLKuehn Law Encourages PWOD, NURO, BHLB, and BRKL Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 1y agoECORNUROelectroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and WellnessGlobeNewswireThe Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST
- 1y agoECORNURONeuroMetrix to be Acquired by electroCoreGlobeNewswireWOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. ("NeuroMetrix" or the "Company") (NASDAQ:NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc.
- 2y agoNURONeuroMetrix Reports Q3 2024 Business HighlightsGlobeNewswireWOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The Company develops
- 2y agoNURONeuroMetrix Reiterates its Review of Strategic AlternativesGlobeNewswireWOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this
- 2y agoNURONeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoNURONeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic OptionsGlobeNewswireWOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to
- 2y agoNURONeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference CallGlobeNewswireWOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on
- 2y agoNURONeuroMetrix Reports Q1 2024 Business HighlightsGlobeNewswireWOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact
- 2y agoNURONeuroMetrix Announces Steps Taken to Enhance Shareholder ValueGlobeNewswireJoshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder
- 2y agoNUROTranscutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN) - NCT06324344ClinicalTrials.govChange in pain level at 8 weeks from baseline, Change in vibration perception threshold at 8 weeks from baseline, Change in sural nerve conduction velocity and amplitude at 8 weeks from baseline, Changes in Quality of Life at 8 weeks from baseline
- 2y agoNURONeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyGlobeNewswireWOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately
- 2y agoNURONeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaGlobeNewswireWOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in
- 2y agoNUROEcho Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be FiredACCESS NewswireNURO stock price has declined 99% since its IPOGozani has received compensation of over $10 million since the IPOGozani was charged by the FTC for various wrongdoings at NUROGozani apparently personally paid the FTC $4
- 2y agoNUROEcho Lake Capital Calls for the Liquidation of Neurometrix, Inc.ACCESS Newswire- Stock trades significantly below its net cash per share- Questions the Board's ability and/or desire to create shareholder value- Notes tremendous destruction of shareholder value under company's leadership- Sees no
- 2y agoNURONeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsGlobeNewswireWOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to
- 2y agoNURONeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallGlobeNewswireWOBURN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the
- 2y agoNURONeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueGlobeNewswireWOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative
- 2y agoNURONeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024GlobeNewswireWOBURN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024. This live, interactive, online event will
- 2y agoNURONeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)GlobeNewswireWOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute
- 2y agoNURONeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)GlobeNewswireWOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation
- 2y agoNURONeuroMetrix Announces One-for-Eight Reverse Stock SplitGlobeNewswireWOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the
- 3y agoNURONeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023GlobeNewswireWOBURN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023. This live, interactive, online
- 3y agoNURONeuroMetrix Inc. (NURO) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoNURONeuroMetrix Reports Q3 2023 Business HighlightsGlobeNewswireWOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023. The Company's
- 3y agoNURONeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallGlobeNewswireWOBURN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26,
- 3y agoNURONeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with FibromyalgiaGlobeNewswireWOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA). As a Proud Sponsor NeuroMetrix
- 3y agoNURONeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023GlobeNewswireWOBURN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023. This live, interactive, online event will
- 3y agoNURONeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023GlobeNewswireWOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023. This live, interactive, online event will
- 3y agoNURONeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallGlobeNewswireWOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023.
- 3y agoNURONeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaGlobeNewswireWOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced expansion of its sales force to drive further adoption of Quell® Fibromyalgia, which is the first and only medical
- 3y agoNURORecent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsGlobeNewswireWOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes. Ke
- 3y agoNURODiabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyGlobeNewswireWOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific poster was titled
- 3y agoNUROQuell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)GlobeNewswireWOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled
- 3y agoNURONeuroMetrix Reports Q1 2023 Financial ResultsGlobeNewswireWOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company's mission is to reduce the impact of
- 3y agoNURONeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference CallGlobeNewswireWOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023. The
- 3y agoNURONeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual MeetingGlobeNewswireWOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In
- 3y agoNURONeuroMetrix Reports Q4 and Full Year 2022 Financial ResultsGlobeNewswireWOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company's mission is to
- 3y agoNURONeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference CallGlobeNewswireWOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on
- 3y agoNURONeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral NeuropathyGlobeNewswireWOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that leverages gold-standard
- 4y agoNURONeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual MeetingGlobeNewswireWOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in
- 4y agoNURONeuroMetrix Announces Strategic Launch of Quell FibromyalgiaGlobeNewswireWOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the
- 4y agoNURONeuroMetrix Reports Q3 2022 Financial ResultsGlobeNewswireWOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company's
- 4y agoNURONeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference CallGlobeNewswireWOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The
- 4y agoNUROEfficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions - NCT05540002ClinicalTrials.govThe Brief Pain Inventory Interference Scale (BPI), Pain Catastrophizing Scale (PCS), Pain Disability Index (PDI), (and 9 more...)
- 4y agoNURONeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics BusinessGlobeNewswireWOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organiz
- 4y agoNURONeuroMetrix Reports Q2 2022 Financial ResultsGlobeNewswireWOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company's mission is to reduce the impact of neurological d
- 4y agoNURONeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference CallGlobeNewswireWOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call